PTCT PTC Therapeutics Inc

Royalty Pharma plc announced the acquisition of the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi for an upfront payment of $240 million and up to $60 million in sales-based milestone payments. This transaction gives Royalty Pharma 100% of the tiered royalty on worldwide net sales of Evrysdi, with increased royalties starting in the first quarter of 2026.

PTC Therapeutics has amended its royalty purchase agreement with Royalty Pharma, selling its remaining interest in the Evrysdi royalty for $240 million upfront and potential additional payments. This transaction grants Royalty Pharma 100% ownership of the Evrysdi royalty, providing immediate cash and potential milestones for PTC. The deal aims to monetize the Evrysdi royalty and enhance PTC's financial liquidity.

Pacer Advisors Inc. reduced its stake in PTC Therapeutics (NASDAQ:PTCT) by 32% in Q3, selling 236,851 shares but still retaining 503,966 shares valued at approximately $30.93 million. This comes amidst significant insider selling, with company executives disposing of 358,330 shares worth $26.77 million in the last 90 days. Despite a recent earnings beat, analysts maintain a "Hold" rating with an average price target of $76.

PTC Therapeutics (NASDAQ:PTCT) insider Eric Pauwels recently sold 20,508 shares of the company's stock for over $1.5 million. This sale, part of a larger transaction in which Pauwels sold 64,000 shares, reduced his stake by 22.57% to 70,373 shares. The company's stock currently trades around $77.70, with analysts holding a "Hold" consensus rating and a target price of $76.00.

PTC Therapeutics, Inc. announced that CEO Matthew B. Klein, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9 a.m. PST/12 p.m. EST. The presentation will be webcast live on the company's website and archived for 30 days. PTC is a global biopharmaceutical company focusing on rare disorders.

Voya Investment Management LLC significantly increased its stake in PTC Therapeutics, Inc. to $17.48 million, now owning 0.36% of the company. Despite this, company insiders have been net sellers, disposing of over $25 million worth of shares recently. Analysts maintain a "Hold" consensus rating for PTC Therapeutics with an average price target of $76.00.